OCUGEN OCGN 深 沪
交易中 03-25 11:45:30 美东时间
2.075
+0.155
+8.07%
华盛通- 最 高2.10
- 今 开1.98
- 成交量 515.50万股
- 最 低 1.975
- 昨 收 1.92
- 总市值 6.80亿
- 52周最高 2.725
- 市盈率 静 --
- 换手率 1.57%
- 52周最低 0.57
- 委 比 85.00%
- 总股本 3.28亿
- 历史最高 18.77
- 量 比 1.10
- 振 幅 6.51%
- 历史最低 0.17
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls
Ocugen stock falls after Phase 2 OCU410 data for dry AMD trails interim results, despite lesion reduction.
03-24 22:40
BUZZ-U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder
BUZZ-U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 24 (Reuters) - U.S. stock index futures pointed to a lower open on
03-24 21:10
Ocugen to Host March 24 Webcast on Phase 2 OCU410 Data at 8 a.m. EDT
Ocugen to Host March 24 Webcast on Phase 2 OCU410 Data at 8 a.m. EDT Ocugen scheduled a conference call and live webcast at 8 a.m. EDT on March 24, 2026 to discuss the full Phase 2 ArMaDa clinical trial data for OCU410 in geographic atrophy. Key opinion leaders Lejla Vajzovic and Jay Chhablani were
03-23 19:11
Ocugen raises USD 15 million from partial exercise of warrants for 10 million shares
Ocugen raises USD 15 million from partial exercise of warrants for 10 million shares Ocugen reported that an institutional investor exercised warrants on March 12, 2026, purchasing 10 million common shares. The partial warrant exercise generated gross proceeds of USD 15 million. Ocugen said the proc
03-20 20:01
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
美股牛股 | OCUGEN飙升近30%，机构首次覆盖该公司并给予高额目标价；纳微半导体大涨近25%
OCUGEN飙升近30%，机构首次覆盖该公司并给予高额目标价；纳微半导体大涨近25%，推出适用于人工智能数据中心的两款新产品>>
03-12 16:40
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Why Is Ocugen Stock Soaring Today?
Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target.
03-12 04:21
Oppenheimer Initiates Coverage On Ocugen with Outperform Rating, Announces Price Target of $10
Oppenheimer analyst Leland Gershell initiates coverage on Ocugen (NASDAQ:OCGN) with a Outperform rating and announces Price Target of $10.
03-11 19:38
Ocugen Seeks Court Validation of Charter Amendment Dispute
Ocugen ( ($OCGN) ) has provided an announcement. On June 28, 2024, Ocugen’s sha...
03-05 00:28
